TUESDAY, March 31, 2020 (HealthDay News) — Real-world data support the benefit of using the Medtronic MiniMed 670G insulin pump system for glycemic control in type 1 diabetes, according to a study presented at the virtual meeting of The Endocrine Society, held from March 28 to 31.
Robert Alan Vigersky, M.D., and colleagues from Medtronic Diabetes in Washington, D.C., analyzed system data for 118,737 individuals with type 1 diabetes aged ≥7 years who enabled Auto Mode on their MiniMed 670G system. The authors sought to determine the mean percentage of overall time spent <54 mg/dL/<70 mg/dL (time below range [TBR]), between 70 and 180 mg/dL (TIR), and >180 mg/dL/>250 mg/dL (time above range [TAR]). The impact of Auto Mode was examined among 51,254 individuals with at least seven days of sensor glucose data for Auto Mode turned ON and turned OFF.
The researchers found that the system data TIR was 71.3 percent. User-wise data of Auto Mode OFF versus ON showed a mean of 70.3 percent of time spent in Auto Mode; the analysis showed an increase in TIR from 60.9 to 69.9 percent and decreases in both TBR and TAR for Auto Mode versus Manual Mode.
“Our results demonstrate that the glycemic control using the MiniMed 670G in the real world is excellent,” Vigersky said in a statement.
The study was funded by Medtronic Diabetes.
Copyright © 2020 HealthDay. All rights reserved.